

Daftar Pustaka

- Akl M. R., Nagpal P., Ayoub N. M., Prabhu S. A., Gliksman M., Tai B., Hatipoglu A., Goy A., Suh K. Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. *Oncotarget*. 2015; 6: 28693-28715.
- Al-Humood SA, Al-Qallaf AS, AlShemmari SH, Francis IM, Junaid TA, Marouf RA, et al. Genotypic and phenotypic differences between nodal and extranodal diffuse large B-cell lymphoma. *J Histochem Cytochem*. 2011; 59: 918-31.
- Caruana, Ignazio., Barbara, Savoldo., Valentina, Hoyos., Gerrit, Weber., Hao, Liu., Eugene, S, Kim., Michael, M, Ittmann., Dario, Marchett., Gianpietro, Dotti. (2015) "Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes" *Nat Med*; 21(5): 524-529.
- Fernandes dos Santos TC, Gomes AM, Paschoal ME, Stelling MP, Rumjanek VM, Junior Ado R, Valiante PM, Madi K, Pereira de Souza HS, Pavão MS, Castelo-Branco MT. Heparanase expression and localization in different types of human lung cancer. *Biochim Biophys Acta*. 2014 Aug;1840(8):2599-608. doi: 10.1016/j.bbagen.2014.04.010. Epub 2014 Apr 18. PMID: 24747732.
- Friedberg, J. W., & Fisher, R. I. (2008). Diffuse large B-cell lymphoma. *Hematology/oncology clinics of North America*, 22(5), 941–ix. <https://doi.org/10.1016/j.hoc.2008.07.002>
- Gouveia, G. R., Siqueira, S. A., & Pereira, J. (2012). Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. *Revista brasileira de hematologia e hemoterapia*, 34(6), 447–451. <https://doi.org/10.5581/1516-8484.20120111>
- Hammond, Edward., Khurana, Ashwani., Shridhar, Viji., Dredgeet, Keith. (2014). "The role of heparanase and sulfatases in the modification of heparan sulfate proteoglycans within the tumor microenvironment and opportunities for novel cancer therapeutics". *Front Oncol*; 4: 195.
- Jayatilleke, K.M., Hulett, M.D. Heparanase and the hallmarks of cancer. *J Transl Med* 18, 453 (2020). <https://doi.org/10.1186/s12967-020-02624-1>
- Josette William, MD, PhD, Yi-Hua Chen, MD, C-MYC Expression in Diffuse Large B-Cell Lymphoma and Correlation With Hans Classification and Proliferation index, *American Journal of Clinical Pathology*, Volume 138, Issue suppl_1, July 2012, Page A291, <https://doi.org/10.1093/ajcp/138.suppl1.270>
- Kumar V, Abbas AK, Aster JC. Robbins Basic Pathology. 9th ed. Philadelphia: Elsevier; 2015. P.95-96.
- Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. *Science* 1983; 220: 611–3.
- Nguyen, L., Papenhausen, P., & Shao, H. (2017). The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. *Genes*, 8(4), 116. <https://doi.org/10.3390/genes8040116>
- Padala SA, Kallam A. Diffuse Large B Cell Lymphoma. [Updated 2021 May 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557796/>
- Secchi, M. F., Masola, V., Zaza, G., Lupo, A., Gambaro, G., & Onisto, M. (2015). Recent data concerning heparanase: focus on fibrosis, inflammation and cancer. *Biomolecular concepts*, 6(5-6), 415–421. <https://doi.org/10.1515/bmc-2015-0021>
- Sehn, L. H., & Salles, G. (2021). Diffuse Large B-Cell Lymphoma. *The New England journal of medicine*, 384(9), 842–858. <https://doi.org/10.1056/NEJMra2027612>



- Shortt, J., & Johnstone, R. W. (2012). Oncogenes in cell survival and cell death. Cold Spring Harbor perspectives in biology, 4(12), a009829. <https://doi.org/10.1101/cshperspect.a009829>
- Vlodavsky, I., Singh, P., Boyango, I., Gutter-Kapon, L., Elkin, M., Sanderson, R. D., & Ilan, N. (2016). Heparanase: From basic research to therapeutic applications in cancer and inflammation. *Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy*, 29, 54–75. <https://doi.org/10.1016/j.drug.2016.10.001>
- Weissmann, M., Arvatz, G., Horowitz, N., Feld, S., Naroditsky, I., Zhang, Y., Ng, M., Hammond, E., Nevo, E., Vlodavsky, I., & Ilan, N. (2016). Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, 113(3), 704–709. <https://doi.org/10.1073/pnas.1519453113>
- Zong F, Fthenou E, Wolmer N, Hollósi P, Kovalszky I, Szilák L, Mogler C, Nilsson G, Tzanakakis G, Dobra K. Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells. *PLoS One* 2009; 4: e7346.